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ABSTRACT
Chlamydia pneumoniae seropositivity is associated with cardiovascular disease and HIV infection. Cell-
mediated immune responses are important for control of C. pneumoniae, and such responses may be
impaired in HIV-infected patients. An assay for detection of interferon (IFN)-c in whole blood
stimulated with C. pneumoniae antigen was developed and studied in HIV-infected patients and
uninfected controls. Among 34 HIV-infected patients, none had an IFN-c response to C. pneumoniae
antigen, compared with five of 32 healthy controls (p < 0.001). Fewer HIV-infected individuals elicited a
serum IgG response when tested with a commercial enzyme immunoassay (p 0.009), but this was not so
for serum IgA (p 0.12). Additionally, the IFN-c and antibody assays showed a trend towards a bivariate
response in normal controls. This indicates that cellular and antibody responses against C. pneumoniae
may be mutually exclusive, with potential implications for the role of this organism in the genesis of
cardiovascular disease in both immunocompetent and HIV-infected populations.
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INTRODUCTION
Chlamydia pneumoniae is an intracellular organism
thought to cause acute and chronic infections
[1,2]. Chronic infection with this organism has
been of particular interest because of a putative
association with arteriosclerosis [3,4]. This associ-
ation is based on significant differences in
C. pneumoniae IgA titres between patients with
arteriosclerotic disease and healthy controls [5],
detection and propagation of C. pneumoniae from
atherosclerotic plaques [6], and animal and
in-vitro studies which support a role for infection
in initiation and progression of arteriosclerotic
disease [7,8].
Protection from infection by this intracellular
pathogen has been shown in mice to depend
largely on cell-mediated immunity, and partic-
ularly secretion of the cytokine interferon (IFN)-c
[9]. Human studies of cell-mediated immunity
in vitro with lymphocyte proliferation assays have
revealed that 84% of healthy volunteers respond to
C. pneumoniae [10]. Stimulation of human periph-
eral blood lymphocyteswithC. pneumoniae for 24 h
induced IFN-c protection [11]. An efficient cellular
immune system thus seems to be important for
eradication of C. pneumoniae infection.
In addition to the established link between
C. pneumoniae and cardiovascular events, an
increased risk of cardiovascular events in HIV-
infected individuals has been shown recently
[12–14]. Although these findings are controversial,
it seems likely that at least some of this risk is
unrelated to anti-retroviral treatment. One possi-
bility is that HIV patients have a reduced cell-
mediated immune response to C. pneumoniae, and
that this could contribute to the increased risk of
cardiovascular events. Therefore, the present study
aimed to investigate the cellular immune response
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to C. pneumoniae by measuring whole blood IFN-c
secreted in response to C. pneumoniae antigen in
HIV-infected patients and controls.
MATERIALS AND METHODS
Patients and controls
Healthy volunteers (n = 32; mean age 34.2 ± 9.8 years) were
recruited among staff of the Alfred Hospital, Melbourne,
Australia. HIV antibody-positive patients (n = 34; mean age
41.6 ± 9.0 years) were recruited from among outpatients and
inpatients of the Alfred Hospital during the same time period.
The CD4 counts and virological status of the HIV-infected
patients are shown in Table 1. Recruitment consent and all
subsequent investigations were approved by the Human
Research and Ethics Committee of Alfred Hospital.
The whole blood C. pneumoniae IFN-c assay
A new method of measuring IFN-c release from whole blood
was used. The test is rapid and simple, and demonstrates
T-helper 1-type cellular immunity by detecting IFN-c pro-
duced in whole blood stimulated with specific antigen(s). The
principle of the test takes advantage of the fact that individuals
primed in vivo with exogenous or endogenous antigen have
lymphocytes in their blood that maintain an immunological
memory for the priming antigen. In-vitro addition of antigen
to blood taken from such individuals results in rapid
re-stimulation of antigen-specific effector (memory) T-cells,
followed by release of the cytokine IFN-c, which is then used
as a specific marker for detecting a cellular immune response
mounted to the antigen (recall response).
The method was modified slightly from that described for
tuberculosis [15]. A QuantiFERON-CMI kit (Cellestis, Park-
ville, Victoria, Australia) was used in conjunction with a
purified C. pneumoniae antigen (see below), free of cellular
material, thereby reducing the risk of cross-reaction with
human proteins. This antigen does not cross-react serologically
with C. trachomatis. In brief, aliquots (1 mL) of undiluted
(heparinised) whole blood were incubated overnight with C.
pneumoniae antigen at a concentration of 10 mg ⁄L blood, and
also with phosphate-buffered saline as a negative control, and
phytohaemaglutinin (PHA) as a positive control. Following
overnight incubation, plasma samples were harvested for IFN-
c quantification by a single-step sandwich-ELISA. Plasma
samples were reacted simultaneously with anti-IFN-c antibod-
ies bound to the solid phase and enzyme-labelled anti-IFN-c
antibodies in solution for 60 min. Unbound material was
removed by washing, followed by the addition of enzyme
substrate. The reaction was terminated after 30 min and the
amount of colour development was measured spectrophoto-
metrically. The concentration of IFN-c in each plasma sample
was then calculated by comparison with kit standards.
Preparation of antigen
All IFN-c analyses were performed within 12 h of obtaining
blood samples. The antigen used for the IFN-c assay was
prepared by culturing C. pneumoniae (VR1310) in BHK (baby
hamster kidney) cells. BHK cells were infected with one
inclusion-forming unit ⁄ cell in infection medium, comprising
RPMI-1640 (Gibco, Paisley, UK) 49% v ⁄v, fetal calf serum
(Biological Industries, Haemex, Israel) 2.5% v ⁄v, phosphate-
buffered saline 48.5% v ⁄v and gentamicin 12.5 mg ⁄L, and
were then centrifuged at 700 g for 20 min at 35C. After 2 h,
the medium was changed to RPMI-1640 97.5% v ⁄v, fetal calf
serum 2.5% v ⁄v, gentamicin 25 mg ⁄L and cycloheximide
1 mg ⁄L. Following incubation for 3 days at 35C in CO2 5%
v ⁄v, the infection was confirmed by immunofluorescence. The
elementary bodies were purified as described by Knudsen
et al. [16] and checked for purity by electron microscopy
following negative staining [16]. The amount of antigen used
(10 mg ⁄L blood) was determined by the generation of dose
response curves in preliminary experiments (results not
shown).
Serological assays and PCR experiments
Commercially available enzyme immunoassays for IgA and
IgG (Labsystems, Helsinki, Finland) were used for antibody
detection. These assays have been shown to be the most
reliable antibody assays for acute infections and do not
generate false-positive reactions in the presence of a number
of non-chlamydial antigens [17,18].
A nested PCR that targeted part of the MOMP gene in
C. pneumoniae was used to assess the presence of C. pneumoniae
in peripheral blood mononuclear cells of HIV-infected patients
and controls as described previously [19,20].
Table 1. Characteristics of HIV-infected patients and controls, including their cellular and humoral immune responses to
Chlamydia pneumoniae antigens
Age
(years)
CD4
count
(cells/lL)
CD4
lowest
recorded
count
Viral
load
(copies/mL)
PHA
IFN-c
(IU/mL)
Chlamydia
pneumoniae
IFN-c
(IU/mL)
Chlamydia
pneumoniae
serum IgA
(EIU)
Chlamydia
pneumoniae
serum IgG
(EIU)
HIV-infected patients (n = 34)
Mean 41.6 397 169 14 779 45 6 8 30
Median 40.0 337 145 2275 30 2 5 22
Minimum 20 7 1 50 0 0 0 0
Maximum 63 1337 525 100 000 244 47 46 146
SD 9.0 308 137 28 085 52 11 10 31
Normal controls (n = 32)
Mean 34.2 N ⁄A N ⁄A N ⁄A 29 35 7 50
Median 32.0 N ⁄A N ⁄A N ⁄A 21 16 6 46
Minimum 21 N ⁄A N ⁄A N ⁄A 0 1 0 2
Maximum 58 N ⁄A N ⁄A N ⁄A 125 213 33 219
SD 9.8 N ⁄A N ⁄A N ⁄A 29 49 7 48
PHA, phytohaemagglutinin; N ⁄A, not applicable; IU, international units; EIU, enzyme immunosorbent units; SD, standard deviation.
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Statistics
Results were analysed with SPSS statistical software for
Windows (SPSS Inc., Chicago, IL, USA). The Mann–Whitney
U-test, the chi-squared test and Fisher’s exact test were used to
compare frequencies between the groups.
RESULTS
The whole blood C. pneumoniae IFN-c assay
The assay was standardised with normal con-
trols. As shown in the upper panels in Fig. 1,
there was no clear cut-off level for positivity in
the developed IFN-c assay. None of the controls
had both a high antibody response (Th2) and a
high IFN-c response (Th1) (Fig. 1). There
appeared to be a trend towards a bivariate
response in the control group; that is, no cellular
response to C. pneumoniae was seen if there was
a humoral response, and vice versa. However,
this difference did not reach statistical signifi-
cance (p 0.30 for IgG and p 0.14 for IgA). With
an arbitrary cut-off level of 50 IU ⁄mL being
taken to define a positive reaction, none of the
HIV-infected individuals was positive
(Fig. 1C,D), compared with five of the healthy
controls (Fig. 1A,B; p 0.02).
Antibody response and PCR experiments
The antibody results can be analysed using either
conventional cut-off values or by a comparison of
means. The conventional cut-off value for a
positive IgA is 1:16, and that for IgG is 1:64. By
these criteria, three of the 34 HIV-infected patients
had a positive IgG response, and five had a
Fig. 1. Relationship between interferon-c response and serum IgG and IgA response to Chlamydia pneumoniae in normal
controls and HIV-infected patients.
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positive IgA response, compared with eight of
32 controls who were positive for IgG and three of
32 who were positive for IgA (Table 1). The mean
values in the HIV-positive patients were 29.6 and
7.8 EIUs for IgG and IgA, respectively, compared
with 50.0 and 7.3 EIUs, respectively, for the
controls. C. pneumoniae DNA was not detected
by PCR in peripheral blood mononuclear cells
from any of the HIV-infected individuals or
normal controls.
Comparison between HIV-infected patients and
controls
Details of comparisons between the two groups
appear in Table 1. The CD4 count at the time of
study, the lowest recorded CD4 count (CD4
nadir) and the viral load at the time of the study
are shown for the HIV antibody-positive patients.
There was no correlation between any of these
parameters and the results obtained by serology
or the IFN-c release assay (data not shown).
Since C. pneumoniae serology depends on sex
and age, ten controls were chosen to match the
HIV antibody-positive group according to sex
and age. The mean ages in this analysis were
41 years for the controls and 42 years for the HIV-
positive patients. The mean IFN-c response was
43 IU ⁄mL in the controls vs. 6 IU ⁄mL in the HIV-
positive patients (p 0.002). The mean PHA
response was higher in the HIV-positive patients
than in the matched controls (45 IU ⁄mL vs.
35.8 IU ⁄mL; p 0.72, Mann–Whitney U-test). How-
ever, the mean IgA response was 11 EIUs in
controls vs. 8 EIUs in the HIV-positive patients
(p 0.12), while the mean IgG response was
76 EIUs in controls vs. 30 EIUs in HIV-positive
patients (p 0.009).
DISCUSSION
This is one of the first studies to examine the
cellular immune response to C. pneumoniae. The
main findings of the study were two-fold: first,
that in HIV-infected patients there was a weak
cellular immune response and a lower IgG
response compared with healthy controls; and
second, that in healthy controls there was an
apparent bivariate response to C. pneumoniae with
regard to cellular and humoral immune response,
i.e., there was a response of one or the other type,
but not both.
It was notable that the IFN-c response to PHA
in the HIV-infected patients was not reduced, but
was greater than in the healthy control group.
This could be a result of the direct stimulatory
effect on T-lymphocytes, which is characteristic of
PHA. This also indicated that a response to PHA
was not an optimal measure of immunocompe-
tence. Although the present study looked at
C. pneumoniae immunity in a novel way and the
findings were clear, there were some reservations
regarding the interpretation of the study. The first
is that the numbers involved were relatively
small. The second is the difficulty in correlating
the results with true infection, either chronic or
acute, given the lack of a standard such as culture.
In addition, PCR-based studies suffer from prob-
lems of reproducibility [21–23].
The finding of a decreased cellular response in
HIV-infected individuals was consistent with
known HIV immunology [24]. Furthermore, the
findings were also consistent with previous stud-
ies which have shown that acute infection does
not always induce an antibody response to
C. pneumoniae in HIV-negative patients [25]. Such
previous studies, including those linking chronic
C. pneumoniae infection to vascular disease, have
also been based largely on antibody responses
[26]. Nucleic acid-based tests have been used, but
are problematic [21,22]. For example, Apfalter
et al. [23] showed that problems with false-posit-
ive reactions in negative controls tend to occur in
laboratories with high detection rates of C. pneu-
moniae in monocytes by PCR.
It has been thought that the cellular immune
response may be more important in clearing this
intracellular organism [27]. The present study
found a decreased IFN-c immune response to
Chlamydia in HIV-infected patients, consistent
with studies on the serologically distinct serovar
C. trachomatis [27]. However, the previous study
used the conventional technique of measuring
IFN-c response from peripheral blood mononu-
clear cells rather than whole blood. A separate
study examined lymphocyte proliferation rates to
Chlamydia antigens in patients with coronary
heart disease [28], and showed an association in
comparison with normal controls for men but not
for women. The strength of the antibody
responses did not correlate with the lymphocyte
proliferation rates. Furthermore, specific anti-
chlamydial responses have also been seen with
lymphocytes extracted from vascular lesions [29].
Woolley et al. Chlamydia pneumoniae in HIV-infected patients 823
 2004 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 10, 820–825
These studies provide additional data to support
the idea that cellular responses may be important
in the genesis of cardiovascular events. However,
the assay used in the present study is likely to be
more reproducible and less observer-dependent
than the assays used previously.
It may be that the type of immune response to
this organism, rather than chronic infection with
it, defines the critical association with vascular
disease. In the present study, there appeared to be
a bivariate response; the basis of this could be
predetermined genetically or might be related to
the original nature or timing of exposure to a
specific antigen [30,31]. This has been demonstra-
ted in genetically modified mice, where an
increased level of interleukin-10, or a Th2
response, is associated with enhanced suscepti-
bility to infection [9]. Alternatively, the inability
to mount a cellular immune response may lead
to chronic infection and, eventually, to vascular
disease. In the absence of positive PCR results, or
other evidence of the organism, both theories are
speculative at present, but the bias towards IgA
production may indicate chronicity of infection.
The role of such chronic infection in immuno-
suppressed patients, especially with respect to
the possible increase in vascular events noted in
association with HIV infection, remains to be
elucidated.
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